A research team affiliated with UNIST has unveiled a novel extracorporeal blood purification technology that captures and ...

Abstract Extracorporeal hemoadsorption for treating bacteremia has exhibited limited success due to the lack of a clear strategy for effectively ...

U. of Oregon team uncovered a molecule produced by yeast on the skin that has potent antimicrobial properties against a ...

The global fight against infectious diseases faces two major challenges: the threat of new pandemic outbreaks and the ...

Armata Pharmaceuticals ARMP shares have skyrocketed 72.3% in the past month. The massive surge in the stock price was ...

Basilea Pharmaceutica announces commercial availability of antibiotic Zevtera in United States: Allschwil, Switzerland Wednesday, May 21, 2025, 11:00 Hrs [IST] Basilea Pharmaceuti ...

Armata Pharma reports positive data from phase 1b/2a diSArm study of intravenously administered AP-SA02 to treat S. aureus bacteremia: Los Angeles Tuesday, May 20, 2025, 17:00 Hrs ...

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs ...

Armata Pharmaceuticals has posted early validation of its phage platform. The phase 1b/2a trial linked a bacteriophage ...

The yeast Malassezia helps protect the skin from bacterial infections, but only up to a certain point. Scientists at the ...

Scientists uncovered how the resistance protein FusB deflects fusidic acid in bacteria, using atomic-level imaging to reveal a crowbar-like resistance mechanism.

The star of the story is saarvienin A, a brand-new glycopeptide antibiotic produced by an unusual strain of Amycolatopsis, a ...